Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This review highlights that the combination of ultrasound and microneedles can enhance transdermal drug delivery by using physical and energy-driven mechanisms to improve drug penetration into deeper skin layers, with implications for precision medicine and chronic disease treatments.

This study observed that 100% of cancer patients at Dr. Moewardi Surakarta Hospital receiving carboplatin-paclitaxel chemotherapy experienced grade 2 alopecia as an adverse drug reaction.

This article reviews strategies for managing the side effects of cytotoxic chemotherapy in primary healthcare settings and reports no new clinical findings.

In this study, 95% of cancer patients undergoing chemotherapy at Ocean Road Cancer Institute experienced adverse drug reactions, with early symptoms including fatigue, nausea, and loss of appetite.

This study found that VEGF-deficient keratinocytes can form tumors using different aneuploidy and signaling patterns, highlighting VEGF's role beyond angiogenesis in tumor cell growth and survival.

In this study, the Orbis PAXMAN® scalp cooling system showed effectiveness and good tolerability in preventing chemotherapy-induced hair loss in breast cancer patients, particularly those receiving anthracycline-free chemotherapy, though the presence of comorbidities was linked to a higher risk of severe alopecia.

This report details a six-month pharmacy internship in Portugal, where the author engaged in hospital and community pharmacy settings, and discusses scientific topics including obesity medication risks and alopecia treatment options. Results and conclusions are not explicitly reported.

In this case study, a patient experienced darkening of hair color after taking acitretin, an oral retinoid known for potentially causing alopecia, marking a rare and undocumented phenomenon.

This case report describes an 83-year-old man who developed focal neurotoxicity, including paralysis and pain, in the area treated with topical 5-fluorouracil cream for actinic keratoses, suggesting a potential neurotoxic risk associated with the drug, especially in those with a specific genetic deficiency.

This paper offers a detailed overview of B vitamins, detailing their importance for energy, cognition, and metabolism, conditions leading to their deficiencies, symptoms of deficiencies, and the foods rich in these essential nutrients.

This review highlighted that targeted cancer therapies, while generally causing mild toxicities that can be managed, also pose risks of rare but serious side effects like pneumonitis and cardiotoxicities, emphasizing the need for vigilant monitoring and management to ensure patient safety.

This article reviews clinical issues and dermatologist perspectives on managing periungual lesions in patients undergoing docetaxel chemotherapy, but it reports no new clinical outcomes.

This review discusses drugs and mechanisms possibly responsible for chemical- and drug-induced hair loss but presents no new research findings.

This review discusses the potential benefits of folate supplementation to mitigate methotrexate side effects in psoriasis patients and reports no new clinical data, suggesting further randomized controlled trials are needed.

This chapter reviews studies on the side effects of cytostatics and immunosuppressive drugs, detailing various toxicities such as cardiovascular, pulmonary, and neurotoxicity, but provides no new clinical results.

This study found that male germ-free rats fed semisynthetic diets do not grow as rapidly as their conventional counterparts and require dietary biotin for normal metabolism and folic acid biosynthesis.

This review discusses the skin side effects associated with targeted cancer therapies and reports no new clinical results; it emphasizes the need for empirical management based on expert opinion.

This congress summary highlights the COMEF 2023 event, which focused on medical ethics, education, and health through discussions with the theme "Learn, practice, excel," but reports no new research findings.

In this mouse study, applying a vasoconstrictor before chemotherapy did not create a leukemia sanctuary or significantly impact survival outcomes, suggesting it may not interfere with leukemia treatment.

Some new drugs show potential for treating blood cancers but have serious side effects and need more research.

This article discusses the interest in folic acid antagonists for leukemia treatment, noting their potential mechanism of interfering with cellular growth, but reports no new clinical results.

In this report, three patients experiencing levetiracetam-induced hair loss showed improvement with zinc sulfate supplementation while their seizures remained controlled.

This study reports that hair loss may be a rare side effect of levetiracetam in epilepsy patients and appears reversible upon dose reduction or cessation.

This study identified mefloquine as a potent inducer of lethal ER stress that effectively eliminated vemurafenib-resistant and sensitive melanoma cells, suggesting its potential for repurposing as a melanoma treatment.

This research reports that arsenic trioxide achieved a complete remission rate of 87% in patients with relapsed acute promyelocytic leukemia, though its use involves manageable toxicities.

This study found that valproic acid may interfere with the leucine metabolic pathway by inhibiting 3-methylcrotonyl-CoA carboxylase and biotinidase, which could contribute to side effects like skin rash and hair loss in patients.

This review discusses the repurposing of auranofin for oncological and non-oncological uses and highlights its early-stage clinical trial findings, suggesting further exploration of its therapeutic potential.

In this study, a sole diet of Leucaena leucocephala caused hypothyroidism and poor weight gain in steers, but mineral supplementation improved some symptoms without normalizing thyroid hormone levels.

This study observed that a combination of low-dose cyclophosphamide and vinorelbine appears safe and has promising antitumor activity in patients with metastatic breast cancer resistant to anthracyclines and taxanes, achieving a 44% objective response rate at 6 months with manageable toxicity levels.